Zydus Lifesciences gets CDSCO panel nod to conduct bioequivalence study of Eltrombopag for oral suspension Dr. Divya Colin3 April 2025 6:00 PM ISTNew Delhi: Zydus Lifesciences has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation...
Eltrombopag Outperforms Standard Therapies for Pediatric Immune Thrombocytopenia in New Trial Medha Baranwal13 Dec 2024 9:30 PM ISTUSA: Findings from the PINES trial suggest that eltrombopag (Promacta) may offer improved outcomes for children with newly diagnosed immune...
Eltrombopag enhances hematologic response in patients with severe aplastic anemia: NEJM Medical Dialogues Editorial Team8 Jan 2022 11:45 AM ISTDelhi: Over the past three decades, efforts to improve the results of standard treatment for patients with Severe Aplastic Anemia have been largely...
USFDA approves use of Promacta for use in children aged 1 and older Meghna A Singhania25 Aug 2015 5:07 PM ISTFDA expands use of Novartis drug Promacta ® to include treatment of children ages 1 and older with chronic immune thrombocytopenia- New oral...
